Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022)

Cancer

Volumn 119, Issue 23, 2013, Pages 4180-4187

  Fangusaro, Jason ^a   Gururangan, Sridharan ^b   Poussaint, Tina Young ^c   McLendon, Roger E ^b   Onar Thomas, Arzu ^e   Warren, Katherine E ^d   Wu, Shengjie ^e   Packer, Roger J ^f   Banerjee, Anu ^g   Gilbertson, Richard J ^e   Jakacki, Regina ^h   Gajjar, Amar ^e   Goldman, Stewart ^a   Pollack, Ian F ^h   Friedman, Henry S ^b   Boyett, James M ^e   Kun, Larry E ^e   Fouladi, Maryam ⁱ  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

bevacizumab; central nervous system tumors; clinical trials; pediatric; toxicity

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE NECROSIS; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EPENDYMOMA; EPISTAXIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMIPARESIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFANT; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT HEMORRHAGE; SCHOOL CHILD; SIDE EFFECT; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR RECURRENCE; VOMITING; WOUND HEALING IMPAIRMENT;

BEVACIZUMAB; CENTRAL NERVOUS SYSTEM TUMORS; CLINICAL TRIALS; PEDIATRIC; TOXICITY;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; HEMORRHAGE; HUMANS; HYPERTENSION; INFANT; INJECTIONS, INTRAVENOUS; NEOPLASM RECURRENCE, LOCAL; PROTEINURIA; YOUNG ADULT;

EID: 84887997111     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28343     Document Type: Article

References (53)

1. Gressett SM, Shah SR,. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009; 43: 490-501.
2. Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol. 1995; 13: 1687-1696.
3. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
4. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A,. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005; 23: 7889-7896.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
6. Cohen MH, Johnson JR, Pazdur R,. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005; 11: 6767-6771.
7. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118: 4771-4779.
8. Muhsin M, Graham J, Kirkpatrick P,. Bevacizumab. Nat Rev Drug Discov. 2004; 3: 995-996.
9. Zhou M, Chen S, Wang W, et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2013; 54: 3874-3879.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
11. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature. 2005; 438: 967-974.
12. Moreira IS, Fernandes PA, Ramos MJ,. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem. 2007; 7: 223-245.
13. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA,. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56: 549-580.
14. Senger DR,. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell. 2010; 21: 377-379.
15. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC,. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012; 7: e49717.
16. Advani A, Kelly DJ, Advani SL, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A. 2007; 104: 14448-14453.
17. Liu X, Hao L, Zhang S, et al. Genetic repression of mouse VEGF expression regulates coagulation cascade. IUBMB Life. 2010; 62: 819-824.
18. Andre N, Verschuur A, Rossler J, Sterba J,. Anti-angiogenic therapies for children with cancer. Curr Cancer Drug Targets. 2010; 10: 879-889.
19. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
20. Cheng SF, Dastjerdi MH, Ferrari G, et al. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol. 2012; 154: 940-948.
21. Glade-Bender J, Kandel JJ, Yamashiro DJ,. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 2003; 3: 263-276.
22. Wang F, Yu S, Liu K, et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology. 2013; 120: 355-361.
23. Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013; 24: 220-225.
24. MacMillan CJ, Furlong SJ, Doucette CD, Chen PL, Hoskin DW, Easton AS,. Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses. J Neuropathol Exp Neurol. 2012; 71: 983-999.
25. Lee YA, Yang CH, Yang CM, et al. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol. 2012; 154: 872-880.
26. Xu Y, You Y, Du W, et al. Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci. 2012; 53: 5221-5226.
27. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95.
28. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11: 69-82.
29. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012; 30: 2509-2515.
30. Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R,. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf. 2012; 10: 67-83.
31. Chang YC, Yu CJ, Chen CM, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012; 36: 387-396.
32. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3′-deoxy-3′- 18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012; 53: 29-36.
33. Reismuller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer. 2010; 54: 681-686.
34. Grignol VP, Olencki T, Relekar K, et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother. 2011; 34: 509-515.
35. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012; 30: 34-41.
36. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010; 69: 337-340.
37. Chen CH, Wu PC, Liu YC,. Intravitreal bevacizumab injection therapy for persistent macular edema after idiopathic macular epiretinal membrane surgery. J Ocul Pharmacol Ther. 2011; 27: 287-292.
38. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol. 1999; 27: 78-86.
39. Fangusaro J, Gururangan S, Jakacki RI, et al. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. J Clin Oncol. 2013; 31: e24-e27.
40. Disel U, Besen AA, Ozyilkan O, Er E, Canpolat T,. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol. 2012; 48: e2-e3.
41. Van Poznak C,. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat. 2010; 122: 189-191.
42. Wynn RL,. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent. 2011; 59: 410-413.
43. Chen S 4th, Karnezis T, Davidson TM,. Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope. 2011; 121: 644-646.
44. Yang SH, Lin JK, Chen WS, et al. Pneumothorax after bevacizumab- containing chemotherapy: a case report. Jpn J Clin Oncol. 2011; 41: 269-271.
45. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010; 122: 181-188.
46. Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA,. Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology. 2009; 73: 1906-1913.
47. Rini BI, Garcia JA, Cooney MM, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol. 2010; 28: e284-e285.
48. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008; 26: 399-405.
49. Tong KA, Ashwal S, Obenaus A, Nickerson JP, Kido D, Haacke EM,. Susceptibility-weighted MR imaging: a review of clinical applications in children. AJNR Am J Neuroradiol. 2008; 29: 9-17.
50. Hapani S, Sher A, Chu D, Wu S,. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010; 79: 27-38.
51. Zhu X, Wu S, Dahut WL, Parikh CR,. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49: 186-193.
52. Hayman SR, Leung N, Grande JP, Garovic VD,. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012; 14: 285-294.
53. Chen HX, Cleck JN,. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009; 6: 465-477.